• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

质量控制图(QCC)在慢性髓性白血病常规定量 BCR-ABL1 监测中的获益。

The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia.

机构信息

Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.

出版信息

PLoS One. 2018 Apr 24;13(4):e0196326. doi: 10.1371/journal.pone.0196326. eCollection 2018.

DOI:10.1371/journal.pone.0196326
PMID:29689094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5916859/
Abstract

Quantitative real-time polymerase chain reaction (qRT-PCR) is state of the art in molecular monitoring of minimal residual disease in chronic myeloid leukemia (CML). In this context, maintenance of assay fidelity and detection of technical inaccuracy are crucial. Beside multiple common negative controls for the clinical sample preparations, quality control charts (QCC) are a common validation tool to sustain high process quality by continuously recording of qRT-PCR control parameters. Here, we report on establishment and benefit of QCC in qRT-PCR-based CML diagnostics. The absolute quantification of BCR-ABL1 fusion transcripts in patient samples is based on coamplification of a serially diluted reference plasmid (pME-2). For QCC establishment the measured Ct values of each pME-2 standard dilution (4-400,000) of a test set resembling 21 sequential qRT-PCR experiments were recorded and statistically evaluated. Test set data were used for determination of warning limits (mean +/- 2-fold standard deviation) and control (intervention) limits (mean +/- 3-fold standard deviation) to allow rapid detection of defined out-of-control situations which may require intervention. We have retrospectively analyzed QCC data of 282 sequential qRT-PCR experiments (564 reactions). Data evaluation using QCCs revealed three out-of-control situations that required intervention like experiment repeats, renewal of pME-2 standards, replacement of reagents or personnel re-training. In conclusion, with minimal more effort and hands-on time QCC rank among the best tools to grant high quality and reproducibility in CML routine molecular diagnosis.

摘要

实时荧光定量聚合酶链反应(qRT-PCR)是慢性髓细胞白血病(CML)微小残留病分子监测的最新技术。在这种情况下,保持检测的准确性和检测技术的不准确性至关重要。除了对临床样本制备的多种常见阴性对照外,质量控制图(QCC)也是一种常见的验证工具,通过连续记录 qRT-PCR 控制参数来维持高质量的过程。在这里,我们报告了 QCC 在基于 qRT-PCR 的 CML 诊断中的建立和益处。患者样本中 BCR-ABL1 融合转录本的绝对定量是基于对一系列稀释的参考质粒(pME-2)的共扩增。为了建立 QCC,记录并统计了测试集(类似于 21 个连续 qRT-PCR 实验)中每个 pME-2 标准稀释液(4-400,000)的测量 Ct 值。测试集数据用于确定警告限制(平均值 +/- 2 倍标准差)和控制(干预)限制(平均值 +/- 3 倍标准差),以快速检测可能需要干预的定义失控情况。我们回顾性分析了 282 个连续 qRT-PCR 实验(564 个反应)的 QCC 数据。使用 QCC 进行的数据评估显示了三种需要干预的失控情况,如实验重复、pME-2 标准更新、试剂更换或人员再培训。总之,只需付出最小的努力和操作时间,QCC 就可以成为保证 CML 常规分子诊断质量和可重复性的最佳工具之一。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ef/5916859/1c78dc0b494a/pone.0196326.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ef/5916859/fed1aa391fe0/pone.0196326.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ef/5916859/9b8e1e268ab4/pone.0196326.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ef/5916859/1c78dc0b494a/pone.0196326.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ef/5916859/fed1aa391fe0/pone.0196326.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ef/5916859/9b8e1e268ab4/pone.0196326.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ef/5916859/1c78dc0b494a/pone.0196326.g003.jpg

相似文献

1
The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia.质量控制图(QCC)在慢性髓性白血病常规定量 BCR-ABL1 监测中的获益。
PLoS One. 2018 Apr 24;13(4):e0196326. doi: 10.1371/journal.pone.0196326. eCollection 2018.
2
A review of the challenge in measuring and standardizing BCR-ABL1.关于测量和标准化BCR-ABL1的挑战的综述。
Clin Chem Lab Med. 2017 Aug 28;55(10):1465-1473. doi: 10.1515/cclm-2016-0927.
3
Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease.BCR-ABL1 定量逆转录聚合酶链反应检测微小残留病的设计和分析验证。
Arch Pathol Lab Med. 2012 Jan;136(1):33-40. doi: 10.5858/arpa.2011-0136-OA.
4
Standardisation of molecular monitoring for chronic myeloid leukaemia.慢性髓性白血病的分子监测标准化。
Best Pract Res Clin Haematol. 2009 Sep;22(3):355-65. doi: 10.1016/j.beha.2009.04.001.
5
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.竞争性巢式PCR与实时PCR检测慢性髓性白血病患者BCR-ABL融合转录本的比较
Leukemia. 2002 Dec;16(12):2447-53. doi: 10.1038/sj.leu.2402730.
6
Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.针对 BCR-ABL1 RNA 的高灵敏度、多重慢性髓系白血病监测系统的分析验证。
J Mol Diagn. 2019 Jul;21(4):718-733. doi: 10.1016/j.jmoldx.2019.03.002. Epub 2019 Apr 23.
7
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.慢性粒细胞白血病中BCR-ABL的定量实时逆转录聚合酶链反应监测显示血液和骨髓样本结果不一致。
Int J Oncol. 2006 May;28(5):1099-103.
8
Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.实时定量 PCR 与数字液滴 PCR 用于监测慢性髓性白血病患者 BCR-ABL1 的比较。
J Mol Diagn. 2020 Jan;22(1):81-89. doi: 10.1016/j.jmoldx.2019.08.007. Epub 2019 Oct 24.
9
Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia.用于确认慢性髓性白血病分子监测中BCR-ABL1国际标准转换因子的赛沛Xpert监测平台
Leuk Res. 2016 Oct;49:47-50. doi: 10.1016/j.leukres.2016.08.007. Epub 2016 Aug 13.
10
Absolute quantification of BCR-ABL1 fusion transcripts in pediatric chronic myeloid leukemia.儿童慢性髓性白血病中BCR-ABL1融合转录本的绝对定量
Leuk Lymphoma. 2016 Sep;57(9):2216-8. doi: 10.3109/10428194.2015.1131272. Epub 2016 Apr 20.

引用本文的文献

1
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia.欧洲白血病网络实验室关于慢性髓性白血病诊断和管理的建议。
Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y. Epub 2023 Oct 4.
2
Reverse Transcription Can Critically Impact the Diagnostic Outcome of Quantitative Real-Time RT-PCR.逆转录可对定量实时逆转录聚合酶链反应的诊断结果产生关键影响。
Cancers (Basel). 2023 Aug 1;15(15):3914. doi: 10.3390/cancers15153914.
3
Separase activity distribution can be a marker of major molecular response and proliferation of CD34 cells in TKI-treated chronic myeloid leukemia patients.

本文引用的文献

1
The concept of treatment-free remission in chronic myeloid leukemia.慢性髓性白血病中无治疗缓解的概念。
Leukemia. 2016 Aug;30(8):1638-47. doi: 10.1038/leu.2016.115. Epub 2016 May 2.
2
Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization.慢性髓性白血病的分子监测:原理与实验室间标准化
Ann Hematol. 2015 Apr;94 Suppl 2:S219-25. doi: 10.1007/s00277-015-2315-1. Epub 2015 Mar 27.
3
An internal validation approach and quality control on hematopoietic chimerism testing after allogeneic hematopoietic cell transplantation.
分离酶活性分布可作为 TKI 治疗慢性髓性白血病患者主要分子反应和 CD34 细胞增殖的标志物。
Ann Hematol. 2020 May;99(5):991-1006. doi: 10.1007/s00277-020-04007-4. Epub 2020 Apr 6.
4
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials.分子 BCR-ABL1 监测系统的诊断性能可能会影响 CML 患者是否纳入停药试验。
PLoS One. 2019 Mar 21;14(3):e0214305. doi: 10.1371/journal.pone.0214305. eCollection 2019.
异基因造血细胞移植后造血嵌合体检测的内部验证方法和质量控制。
Clin Chem Lab Med. 2013 Feb;51(2):363-9. doi: 10.1515/cclm-2012-0230.
4
Standardized definitions of molecular response in chronic myeloid leukemia.慢性髓性白血病分子反应的标准化定义。
Leukemia. 2012 Oct;26(10):2172-5. doi: 10.1038/leu.2012.104. Epub 2012 Apr 16.
5
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.慢性髓性白血病靶向治疗的成功案例:1973 年至 2008 年在瑞典诊断的患者的基于人群的研究。
J Clin Oncol. 2011 Jun 20;29(18):2514-20. doi: 10.1200/JCO.2011.34.7146. Epub 2011 May 16.
6
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.多中心独立评估伊马替尼治疗慢性髓性白血病患者的结局。
J Natl Cancer Inst. 2011 Apr 6;103(7):553-61. doi: 10.1093/jnci/djr060. Epub 2011 Mar 21.
7
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.慢性髓性白血病 BCR-ABL1 转录本测量指南。
Br J Haematol. 2011 Apr;153(2):179-90. doi: 10.1111/j.1365-2141.2011.08603.x. Epub 2011 Mar 8.
8
Impact of long-term storage on stability of standard DNA for nucleic acid-based methods.长期储存对基于核酸方法的标准 DNA 稳定性的影响。
J Clin Microbiol. 2010 Nov;48(11):4260-2. doi: 10.1128/JCM.01230-10. Epub 2010 Sep 1.
9
Application of traditional clinical pathology quality control techniques to molecular pathology.传统临床病理学质量控制技术在分子病理学中的应用。
J Mol Diagn. 2008 Mar;10(2):142-6. doi: 10.2353/jmoldx.2008.070123. Epub 2008 Feb 7.
10
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories.在37个国际实验室中使用统一的多功能对照质粒对BCR-ABL mRNA定量进行标准化。
Leukemia. 2008 Jan;22(1):96-102. doi: 10.1038/sj.leu.2404983. Epub 2007 Oct 18.